Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6066267 | 1.00 | ALDH1A1 (0.31) | ALDH1A1TP53CYP3A4MAPK1SMN1; SMN2 | |
| SCHEMBL16942534 | 0.82 | — | — | |
| SCHEMBL75364 | 0.82 | — | — | |
| SCHEMBL15268337 | 0.81 | — | — | |
| SCHEMBL4669387 | 0.81 | — | — | |
| SCHEMBL676350 | 0.81 | EPHX1 (0.33) | — | |
| SCHEMBL5004300 | 0.81 | EPHX1 (0.33) | — | |
| SCHEMBL9610295 | 0.78 | THRA (0.33) | — | |
| SCHEMBL16338051 | 0.78 | THRA (0.33) | — | |
| SCHEMBL8408097 | 0.77 | THRB (0.35) | ALDH1A1TP53CYP3A4MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4536751-A1 | COMPOSITION BASED ON A POLYMERIZABLE COMPONENT AND A THIXOTROPIC ADDITIVE | ARKEMA FRANCE (FR) | 2025-04-16 | — | — | EP | claimed |
| US-12084571-B2 | Curable compositions based on multistage polymers | ARKEMA FRANCE (FR) | 2024-09-10 | — | — | US | claimed |
| WO-2023237595-A1 | COMPOSITION BASED ON A POLYMERIZABLE COMPONENT AND A THIXOTROPIC ADDITIVE | ARKEMA FRANCE (FR) | 2023-12-14 | — | — | WO | claimed |
| US-20210171760-A1 | CURABLE COMPOSITIONS BASED ON MULTISTAGE POLYMERS | ARKEMA FRANCE (FR) | 2021-06-10 | — | — | US | claimed |
| EP-3814392-A1 | CURABLE COMPOSITIONS BASED ON MULTISTAGE POLYMERS | ARKEMA FRANCE (FR) | 2021-05-05 | — | — | EP | claimed |
| US-20130187095-A1 | THERMOSETTING ADHESIVE COMPOSITIONS | DESIGNER MOLECULES, INC. (US) | 2013-07-25 | — | — | US | claimed |
| US-20260124641-A1 | METHODS FOR FORMING MATTE COATINGS | ARKEMA FRANCE (FR) | 2026-05-07 | — | — | US | disclosed |
| WO-2026041509-A1 | URETHANE (METH)ACRYLATE | ARKEMA FRANCE (FR) | 2026-02-26 | — | — | WO | disclosed |
| EP-4700057-A1 | URETHANE (METH)ACRYLATE | ARKEMA FRANCE (FR) | 2026-02-25 | — | — | EP | disclosed |
| EP-4700056-A1 | URETHANE (METH)ACRYLATE | ARKEMA FRANCE (FR) | 2026-02-25 | — | — | EP | disclosed |
| WO-2025224147-A1 | A CURABLE INKJET COMPOSITION FOR THE MANUFACTURING OF PRINTED CIRCUIT BOARDS | AGFA-GEVAERT NV (BE) | 2025-10-30 | — | — | WO | disclosed |
| EP-4640772-A1 | A CURABLE INKJET COMPOSITION FOR THE MANUFACTURING OF PRINTED CIRCUIT BOARDS | AGFA-GEVAERT NV (BE) | 2025-10-29 | — | — | EP | disclosed |
| EP-4617331-A1 | UV CURABLE INKJET INKS AND INKJET PRINTING METHODS | AGFA NV (BE) | 2025-09-17 | — | — | EP | disclosed |
| US-8530573-B2 | Curable monomer vehicle of (meth)acrylates, vinyl ethers/esters, epoxies, urethanes, polyesters, styrenic compounds or allyl compounds and calcium carbonate; nonabrasive adhesive for microelectronic applications; low coefficients of tthermal expansion; thermosetting pastes; rheology; stacked dies | DESIGNER MOLECULES, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20130187095-A1 | THERMOSETTING ADHESIVE COMPOSITIONS | DESIGNER MOLECULES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-8378017-B2 | Thermosetting adhesive compositions | DESIGNER MOLECULES, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20080075963-A1 | Modified calcium carbonate-filled adhesive compositions and methods for use thereof | DESIGNER MOLECULES, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20070155869-A1 | Mono-functional monomers and methods for use thereof | DESIGNER MOLECULES, INC. | 2007-07-05 | — | — | US | disclosed |
| EP-0975693-B2 | LIQUID CURABLE RESIN COMPOSITION | KONINK DSM N V (NL) | 2006-01-18 | — | — | EP | disclosed |
| EP-0975693-B1 | LIQUID CURABLE RESIN COMPOSITION | DSM NV (NL) | 2002-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124641-A1 | METHODS FOR FORMING MATTE COATINGS | XRCC5, RAD50, GEMIN5 | ALDH1A1 2649/4885TP53 1937/4885CYP3A4 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.